Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
XXB750 · 1 trial · 2 indications
To evaluate the safety and tolerability of XXB750 in adult participants with chronic stable heart failure with reduced or mildly reduced ejection fraction (HFrEF/HFmrEF).
| Arm | Type | Description |
|---|---|---|
| XXB750 Cohort 1 | EXPERIMENTAL | XXB750, single dose |
| Placebo Cohort 1 | PLACEBO_COMPARATOR | Placebo, single dose |
| XXB750 Cohort 2 | EXPERIMENTAL | XXB750, multiple doses |
| Placebo Cohort 2 | PLACEBO_COMPARATOR | Placebo, multiple doses |
| Name | Type | Description |
|---|---|---|
| XXB750 | DRUG | XXB750 |
| Placebo | DRUG | Placebo |
Key Inclusion Criteria: * NYHA functional class II-III * LVEF ≤ 50% documented at screening * Systolic blood pressure 110 - 160 mmHg (cohort 1) or 105-160 mmHg (cohort 2), and heart rate between 50-90 beats per minute, inclusive * Treatment with a stable dose of a beta blocker. * Cohort 1: Treatmen...
XXB750 is an investigational small molecule developed by Novartis AG for heart failure with reduced ejection fraction, or HFrEF. It has been studied in a single Phase 1 clinical trial in participants with reduced or mildly reduced ejection fraction. It is not an approved therapy and remains in clinical development.
XXB750 is being developed for heart failure with reduced ejection fraction, a condition in which the heart muscle does not pump blood efficiently. The Phase 1 study also enrolled participants with mildly reduced ejection fraction, or HFmrEF. The drug is investigational and has no approved indication.
XXB750 is developed by Novartis AG, which trades on the New York Stock Exchange under the ticker NVS. Novartis sponsored the Phase 1 study of the compound in heart failure participants. No other developer or partnership for XXB750 has been announced.
XXB750 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The study was randomized, double-blind, and placebo-controlled, enrolling 27 participants. XXB750 is investigational and has not been approved by the FDA.
XXB750 has been evaluated in one completed Phase 1 trial, NCT05328752, titled a safety and tolerability study in heart failure participants with reduced or mildly reduced ejection fraction. It enrolled 27 adults across the United States and the Netherlands. The trial was randomized, double-blind, and placebo-controlled, and it has completed.